4 years ago

Macomics Raises £4.24M for Immuno-oncology Therapeutics

  • Macomics, a UK-based immuno-oncology company, has secured £4.24 million in funding, bringing its total funding raised to £7.44 million

  • The round was led by Epidarex Capital with participation from new investor Caribou Property Limited and Scottish Enterprise

  • Macomics intends to use the funds to expand its macrophage-based therapeutics R&D portfolio, facilities in Edinburgh and Cambridge, and scientific team to support its accelerated R&D

  • The company specializes in macrophage biology and develops precision medicines to modulate macrophages for cancer treatment

  • They are progressing a diversified portfolio of therapies targeting disease-specific tumor-associated macrophages towards the clinic.

      • ProblemHealthcare

      "Cancer treatment is often ineffective and has severe side effects. Macrophages, a type of white blood cell, play a critical role in the immune response to cancer, but they can also be hijacked by tumors to promote growth and spread."

      Solution

      "Macomics develops precision medicines that target macrophages to modulate their activity, enhancing the body's natural defenses against cancer. By specifically targeting macrophages involved in tumor growth, Macomics aims to create effective and less toxic cancer treatments."

      Covered on